In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDI Sticks to Contract Sales

Executive Summary

While its competitors in the contract sales industry sell themselves as all-purpose marketing outsourcers, Professional Detailing Inc. is sticking to its core business of providing sales reps to pharmaceutical and biotech companies. Although PDI will eventually need to expand and diversify, most likely through acquisition, it should remain successful for some time as a pure play CSO.

You may also be interested in...



The Outsourcing Dilemma

The drug industry has accepted the need to outsource R&D--now, with sales productivity down, and the rising cost and risk of owning too much commercial infrastructure, why not outsource more of the sales effort, too? Big and small pharmas resist the idea but will eventually have to accept it--junior partners in licensing deals are insisting on roles in selling their own products, and Big Pharma must investigate cost-saving solutions.

UK Government Wants To Work With Industry To Identify OTC Switch Candidates

The UK's medicines regulator, MHRA, alongside other government agencies, intends to work together with manufacturers to identify Rx-to-OTC switch candidates. Switch criteria might include “different strength medicines to those available today, combination formulations, or medicines manufacturers already offer without prescriptions in other countries,” NHS England says, in its recently published “Delivery plan for recovering access to primary care.”

Stock Watch: How To Avoid Blockbuster Loss Of Exclusivity Bringing Your Company Down

What is the difference between companies with franchises that rise and then fall into obscurity, and those that keep on rising even after loss of exclusivity?

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel